This Nasal Spray Rapidly Reverses Effects Of Fentanyl Overdose And No, It's Not Naloxone
Portfolio Pulse from Jelena Martinovic
Indivior PLC (NASDAQ:INDV) announced successful results from a pharmacodynamic study showing that its nasal spray, OPVEE, rapidly reverses opioid-induced respiratory depression, a major cause of death from opioid overdose, more effectively than naloxone. The study, part of the OPVEE development program, demonstrated OPVEE's superiority in reversing the effects of remifentanil, a synthetic opioid related to fentanyl, within the first 5 minutes of administration.
March 12, 2024 | 4:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Indivior PLC announced that its nasal spray, OPVEE, effectively reverses opioid-induced respiratory depression faster than naloxone, potentially positioning it as a key tool in addressing the opioid overdose crisis.
The positive results from the pharmacodynamic study not only demonstrate OPVEE's effectiveness but also its potential to become a preferred treatment for opioid overdose, especially in cases involving potent synthetic opioids like fentanyl. This could lead to increased demand for OPVEE, potentially boosting Indivior's revenues and positively impacting its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100